Phase 1/2 study of acalabrutinib and the PI3K delta inhibitor ACP-319 in relapsed/refractory B-cell Non-Hodgkin lymphoma.

Barr, Paul M; Smith, Stephen D; Roschewski, Mark J; O'Brien, Susan M; Sharman, Jeff P; Melear, Jason M; Patel, Priti; Calvo, Roser; Yang, Helen; Spurgeon, Stephen E

Barr, Paul M; Smith, Stephen D; Roschewski, Mark J; O'Brien, Susan M; Sharman, Jeff P; Melear, Jason M; Patel, Priti; Calvo, Roser; Yang, Helen; Spurgeon, Stephen E.

Afiliación

Barr PM; Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY, USA.
Smith SD; University of Washington/Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Roschewski MJ; National Cancer Institute, Bethesda, MD, USA.
O'Brien SM; Chao Family Comprehensive Cancer Center, University of California-Irvine, Irvine, CA, USA.
Sharman JP; Willamette Valley Cancer Institute and Research Center, US Oncology Research, Eugene, OR, USA.
Melear JM; Texas Oncology, Austin, TX, USA.
Patel P; AstraZeneca, South San Francisco, CA, USA.
Calvo R; AstraZeneca, Gaithersburg, MD, USA.
Yang H; AstraZeneca, South San Francisco, CA, USA.
Spurgeon SE; Knight Cancer Institute, Oregon Health and Sciences University, Portland, OR, USA.

Leuk Lymphoma ; 63(7): 1728-1732, 2022 07.

Article en En | MEDLINE | ID: mdl-35200084

Asunto(s)

Linfoma de Células B; Fosfatidilinositol 3-Quinasas; Adenosina; Benzamidas; Humanos; Linfoma de Células B/tratamiento farmacológico; Linfoma de Células B/patología; Pirazinas; Quinolinas

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Linfoma de Células B / Fosfatidilinositol 3-Quinasas Límite: Humans Idioma: En Revista: Leuk Lymphoma Asunto de la revista: HEMATOLOGIA / NEOPLASIAS Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google